Wichita State University (WSU), Antibiotics for Drug-Resistant Bacteria
•Download as PPTX, PDF•
0 likes•177 views
This document summarizes a new class of antibiotics called Liptin that was developed by Wichita State University to address the rise of antibiotic-resistant bacteria. Liptin has shown effectiveness against several gram-positive and gram-negative bacteria as well as mycobacterium in initial in-vitro testing. The technology is patent pending and further funding is needed to conduct initial bioavailability and in-vivo testing to help commercialize the new antibiotic class.
Report
Share
Report
Share
Recommended
Effective, Disposable Medical Gowns
The document summarizes a proposed solution to improve the effectiveness of disposable medical gowns. Current disposable gowns do not meet FDA regulations as they gap and sag, exposing healthcare workers' clothing and risking contamination. The proposed solution extends the gown material up the neck to prevent gaps. This would make disposable gowns compliant with regulations while providing an inexpensive, simple solution. Further development requires demonstrating current gowns' ineffectiveness, such as with a fluorescent particle video test, and pursuing partnerships with manufacturers or the FDA to drive regulatory changes ensuring gown protection.
Dual function camera webinar presentation for webpage
Whiteboard2Boardroom presents innovations from regional universities, hospitals, research organizations to encourage commercialization.
Non-Resistant Antimicrobial Therapy: Treating Superbugs That Cause Nosocomial...
This document discusses a new treatment for hospital-acquired pneumonia (HAP) using a combination of SynAmp, a non-antibiotic compound that enhances antibiotic potency, and an antibiotic. HAP is a major problem with high mortality and increasing antibiotic resistance. The combination therapy is a first-line treatment for HAP that is dosed once daily and shows no resistance after 30 days. It has intellectual property protection and competitive advantages over current treatments. With expedited regulatory pathways, the company aims to launch the primary HAP indication with $200 million in annual sales and expand to other infections. Funding is sought to further develop the pre-clinical candidate.
Safer pork for Vietnamese consumers
This document summarizes a pork safety project in Vietnam from 2012-2022. It notes that pork is the most widely consumed meat in Vietnam, with 80% coming from small farms and slaughtered and sold through traditional retail markets. Food safety is a major issue, with an estimated 1-2 out of 10 people suffering from salmonella annually. The Safe PORK project from 2017-2022 focuses on cheap, simple solutions to improve pork safety in partnership with the private sector. Initial assessments found poor food safety and hygiene across retail. Interventions tested included using slaughter grids instead of floor slaughtering and using ozonized water for disinfection. Tailored packages for retailers included antimicrobial cutting boards and training. Laboratory trials showed lower
Quarantine and surveillance modelling for horticulture biosecurity threats
Quarantine and surveillance modelling for horticulture biosecurity threatsPlant Biosecurity Cooperative Research Centre
This document summarizes research aimed at improving biosecurity decision making for plant pathogens through surveillance modeling. The researchers are developing models and protocols to optimize quarantine zone setting, eradication strategies, and incursion responses. Models of Panama Tropical Race 4 spread and Queensland fruit fly population genetics inform decision processes. The research will deliver publications, conferences, software, and training to benefit state governments, surveillance providers, and horticultural industries through smarter pest detection and control.Disinfestation for market access
This document summarizes a research project aimed at developing new export protocols for Australian and New Zealand horticultural commodities that are effective at controlling quarantine pests, efficient for trade, and economically feasible. The project conducted a review of disinfestation technologies and research, as well as current export protocols. Workshops with industry identified priorities such as standardizing cold treatments and developing protocols to enable air freight exports. Phase 2 will focus on cold treatment data for major fruit fly pests and developing new protocols combining technologies like cold treatments and controlled atmospheres. The research aims to maintain and expand trade by safeguarding industries from pest risks.
Pivot bio final presentation
This document summarizes a business plan for developing and commercializing probiotic products for agriculture. It outlines key activities in the first 5 weeks, which included meeting with academic and industry experts, identifying target crops and customers, and establishing partnerships. The plan focuses on developing probiotic treatments for tomatoes in California, targeting seed companies. An MVP involves testing endophytes on tomato seeds and greenhouse trials. The plan estimates a 10% yield increase could generate $28 million for the company through revenue sharing agreements. Milestones and metrics are identified to advance the project through field trials and commercialization.
Detection and surveillance of phylloxera using qPCR
This document discusses the development of a protocol for detecting the grape pest phylloxera using quantitative PCR (qPCR) in soil samples. The objectives are to create a sampling and detection method that is accurate, sensitive, cost-effective and can be applied to other pests. It aims to obtain endorsement to incorporate the qPCR method into the national phylloxera management standard. The research aims to benefit the wine industry through improved surveillance and early detection of phylloxera, as well as regulators and researchers.
Recommended
Effective, Disposable Medical Gowns
The document summarizes a proposed solution to improve the effectiveness of disposable medical gowns. Current disposable gowns do not meet FDA regulations as they gap and sag, exposing healthcare workers' clothing and risking contamination. The proposed solution extends the gown material up the neck to prevent gaps. This would make disposable gowns compliant with regulations while providing an inexpensive, simple solution. Further development requires demonstrating current gowns' ineffectiveness, such as with a fluorescent particle video test, and pursuing partnerships with manufacturers or the FDA to drive regulatory changes ensuring gown protection.
Dual function camera webinar presentation for webpage
Whiteboard2Boardroom presents innovations from regional universities, hospitals, research organizations to encourage commercialization.
Non-Resistant Antimicrobial Therapy: Treating Superbugs That Cause Nosocomial...
This document discusses a new treatment for hospital-acquired pneumonia (HAP) using a combination of SynAmp, a non-antibiotic compound that enhances antibiotic potency, and an antibiotic. HAP is a major problem with high mortality and increasing antibiotic resistance. The combination therapy is a first-line treatment for HAP that is dosed once daily and shows no resistance after 30 days. It has intellectual property protection and competitive advantages over current treatments. With expedited regulatory pathways, the company aims to launch the primary HAP indication with $200 million in annual sales and expand to other infections. Funding is sought to further develop the pre-clinical candidate.
Safer pork for Vietnamese consumers
This document summarizes a pork safety project in Vietnam from 2012-2022. It notes that pork is the most widely consumed meat in Vietnam, with 80% coming from small farms and slaughtered and sold through traditional retail markets. Food safety is a major issue, with an estimated 1-2 out of 10 people suffering from salmonella annually. The Safe PORK project from 2017-2022 focuses on cheap, simple solutions to improve pork safety in partnership with the private sector. Initial assessments found poor food safety and hygiene across retail. Interventions tested included using slaughter grids instead of floor slaughtering and using ozonized water for disinfection. Tailored packages for retailers included antimicrobial cutting boards and training. Laboratory trials showed lower
Quarantine and surveillance modelling for horticulture biosecurity threats
Quarantine and surveillance modelling for horticulture biosecurity threatsPlant Biosecurity Cooperative Research Centre
This document summarizes research aimed at improving biosecurity decision making for plant pathogens through surveillance modeling. The researchers are developing models and protocols to optimize quarantine zone setting, eradication strategies, and incursion responses. Models of Panama Tropical Race 4 spread and Queensland fruit fly population genetics inform decision processes. The research will deliver publications, conferences, software, and training to benefit state governments, surveillance providers, and horticultural industries through smarter pest detection and control.Disinfestation for market access
This document summarizes a research project aimed at developing new export protocols for Australian and New Zealand horticultural commodities that are effective at controlling quarantine pests, efficient for trade, and economically feasible. The project conducted a review of disinfestation technologies and research, as well as current export protocols. Workshops with industry identified priorities such as standardizing cold treatments and developing protocols to enable air freight exports. Phase 2 will focus on cold treatment data for major fruit fly pests and developing new protocols combining technologies like cold treatments and controlled atmospheres. The research aims to maintain and expand trade by safeguarding industries from pest risks.
Pivot bio final presentation
This document summarizes a business plan for developing and commercializing probiotic products for agriculture. It outlines key activities in the first 5 weeks, which included meeting with academic and industry experts, identifying target crops and customers, and establishing partnerships. The plan focuses on developing probiotic treatments for tomatoes in California, targeting seed companies. An MVP involves testing endophytes on tomato seeds and greenhouse trials. The plan estimates a 10% yield increase could generate $28 million for the company through revenue sharing agreements. Milestones and metrics are identified to advance the project through field trials and commercialization.
Detection and surveillance of phylloxera using qPCR
This document discusses the development of a protocol for detecting the grape pest phylloxera using quantitative PCR (qPCR) in soil samples. The objectives are to create a sampling and detection method that is accurate, sensitive, cost-effective and can be applied to other pests. It aims to obtain endorsement to incorporate the qPCR method into the national phylloxera management standard. The research aims to benefit the wine industry through improved surveillance and early detection of phylloxera, as well as regulators and researchers.
HealthBIO 2020_Prateek Singh_Finnadvance
The document discusses the inefficiencies and high costs of current drug development processes, which rely on animal and 2D cell culture models that do not adequately represent human biology. As a result, 90% of drugs validated in these non-human models fail during human clinical trials. The CEO of Finnadvance, Prateek Singh, proposes that Organ-on-Chip models could help address these issues by providing more representative human models that could save hundreds of millions of dollars and years in the drug development timeline by identifying ineffective drugs earlier. Finnadvance is developing human disease-on-chip platforms using patient-derived cells to model conditions like rare vascular malformations.
Holobiome final presentation 7
Holobiome aims to provide personalized probiotics to help inflammatory bowel disease (IBD) patients remain in remission naturally without side effects. After testing various customer segments, they determined IBD patients were the best fit. Holobiome will partner with suppliers to grow specialized probiotics and conduct research to publish their findings. Their goals are to help patients through cost savings and reduced symptoms while generating revenue through probiotic sales to patients and prescriptions from gastroenterologists.
Hy genesis b - wecan - pitch 160303
This document summarizes a company called HyGenesis that has developed long-lasting antimicrobial technologies to reduce infections. It discusses the problems of hospital and healthcare-acquired infections (HAIs), including the human and financial toll of antibiotic-resistant strains like MRSA. HyGenesis has created Hand Armor and Surface Armor products that provide hours to months of antimicrobial protection through a mechanical killing mechanism. Studies at hospitals and universities have shown the technologies effectively kill pathogens. Management is seeking $350,000 in funding to continue product development and scaling operations to achieve $49 million in global sales by 2020 by targeting the ambulatory care market through multiple sales channels.
Molecular basis of response to (sub)lethal stresses in Tephritid fruit flies
Molecular basis of response to (sub)lethal stresses in Tephritid fruit fliesPlant Biosecurity Cooperative Research Centre
This document summarizes a research project studying the molecular response of tephritid fruit flies to sublethal stresses. The project aims to:
1) Identify the molecular pathways activated in fruit flies exposed to heat, cold, radiation, and parasitic infection stresses.
2) Construct a regulatory network of stress response genes in two key fruit fly pests.
3) Validate specific genes' roles in stress response through functional assays.
The goal is to develop more effective and environmentally friendly postharvest treatments for controlling fruit flies, providing benefits to the horticulture industry, government pest management strategies, and researchers.Nanotechnology in Medical Devices
Nanotechnology is the science of understanding, inventing, and controlling objects which are built in the scales of nanometers (one nanometer is one-billionth of a meter). Using Nanotechnology, manufacturers can compose components such as batteries, robots, or tools at a very small scale which may be later added to medical devices. With advanced scientific developments over a decade, Nanotechnology is proving itself to be useful in the healthcare domain including alternative drug production, cosmetic products, and medical devices. As, in such cases, human safety is the highest priority, these devices or applications which utilize Nanotechnology should be FDA compliant before they are marketed for use...
What to Expect after Getting a COVID-19 Vaccine
Getting a COVID-19 vaccine may cause side effects like pain, swelling, tiredness, or fever, which are signs that the body is building immunity. These side effects should go away within a few days. If side effects persist or worsen after 24 hours, contact a doctor. Taking over-the-counter medicines can help relieve discomfort. Getting the recommended second dose is important even if the first caused side effects, unless a provider advises otherwise.
Covid 19, vaccine and it's development process - Group 1
The document summarizes COVID-19, the development of vaccines for COVID-19, and compares the traditional vaccine development process to the COVID-19 vaccine development process. Specifically:
1) It provides background on COVID-19, describing the virus, symptoms, and transmission routes.
2) It discusses the global effort to develop COVID-19 vaccines, with over 157 candidates in development as of June 2020 and 16 in clinical trials.
3) It summarizes the AstraZeneca/Oxford AZD1222 vaccine, how it works, and results from Phase 1/2 clinical trials showing an immune response.
4) It compares the traditional long vaccine development process, taking 6-20 years, to the accelerated
Global vaccine market Keyword Market PPT 2021-26 | Enhancing Huge Growth and ...
According to the latest report by IMARC Group the global vaccine market size reached a strong growth in 2020.One of the leading trends witnessed in the global vaccines market is the surging cases of the coronavirus disease (COVID-19), which has, till date, resulted in the loss of around half a million lives around the world Looking forward, the market value is projected to reach a strong growth during the forecast period (2021-2026).
All about Covid-19 Vaccine Development
Disclaimer -
The Content belongs to WHO (World Health Organisation). Sharing here is just to spread awareness about Covid-19.
https://www.who.int/docs/default-source/coronaviruse/risk-comms-updates/update37-vaccine-development.pdf?sfvrsn=2581e994_6
Jessica Rockwood-Enfermedades transmitidas por vectores
El 12 de mayo de 2017 celebramos en la Fundación Ramó Areces una jornada con IS Global y Unitaid sobre enfermedades transmitidas por vectores, como la malaria, entre otras.
Julian Entwistle Ian-Enfermedades transmitidas por vectores
El 12 de mayo de 2017 celebramos en la Fundación Ramó Areces una jornada con IS Global y Unitaid sobre enfermedades transmitidas por vectores, como la malaria, entre otras.
Early and accurate detection of bacterial pathogens
This document summarizes a research project that aims to develop accurate and rapid diagnostic tools for detecting exotic bacterial plant pathogens through genome-informed design. The project is developing PCR and LAMP-based diagnostics for key pathogens like Erwinia amylovora and Xanthomonas citri. Field-deployable tools like LAMP and RPA are also being validated for "smart surveillance" directly in the field. The diagnostics and training provided by this research will benefit biosecurity agencies, diagnostic laboratories, and the horticultural industry by facilitating early detection and a rapid response to incursions.
Medical product development & victoria
Victoria, Australia provides eight compelling reasons for undertaking medical product development:
1. Unsurpassed research infrastructure with ongoing research in many medical fields creating new intellectual property daily.
2. Enviable research services infrastructure including three universities doing medical research, and facilities for synchrotron use, nanofabrication, imaging, cytometry, mass spectrometry, microscopy, and pathology.
3. A world class product design and development industry with five ISO13485 accredited consulting groups having deep experience designing products for global certification and markets across many medical product categories.
Biosimilar Development EPTM 2015
Sharing my learning in dealing with complexity and uncertainty and shed some light on:
(a) Understanding the ‘biosimilar paradox’
(b) Accelerating our “QbD” Journey – focusing on ‘from Generics to Biosimilars’
(c) In preparing this talk, collect my thoughts to help NIPTE consider ways for developing its program on Biosimilars to help the Nation improve assurance of quality with confidence and lower costs
(D) Invite the audience to get to know NIPTE and provide us ways to collaborate with industry
Medical Device Biocompatibility
If your medical device has contact with human tissue, it is a safe bet that you will be required to conduct biocompatibility testing. Biocompatibility testing is used to determine the “potential for an unacceptable adverse biological response resulting from contact of the component materials of the device with the body”. The FDA relies heavily on ISO 10993 as the guiding force for biocompatibility testing in medical devices. This ISO standard is rooted in a risk-based approach to testing that the FDA views as the gold standard to ensure that medical devices do not cause adverse local or systemic effects due to contact with human tissue...
Verica mktg 06092010summary
The document summarizes a marketing plan for the Verica Sightline 3D Guided Needle Biopsy System. It describes the unmet need in the field of needle biopsies, specifically the emotional and physical costs to patients from inaccurate or multiple needle insertions. The Verica Sightline aims to improve reliability, safety, and efficiency of biopsies through 3D ultrasound guidance. Key points covered include the target clinical problem, value proposition, market size analysis, and competitive landscape for this medical device product.
BatchMaster ERP for Vaccines
Vaccine development is just the first step in eradicating the pandemic, the real challenge lies in managing and handling its supply chain. An ERP built specifically for Vaccines can be the way out in efficiently fighting these challenges. Go through the presentation to know how exactly an ERP for vaccines helps.
Therapeutic Targeting of Alzheimer's Disease with a Selective Antibody
Whiteboard2Boardroom presents innovations from regional universities, hospitals, research organizations to encourage commercialization.
Urology billing-surgical-supply-growth-and-market-share
According to the new released data companies supplying surgical products for urology have stated that the demand is expected to grow by 10 percent CAGR.
BioEntrepreneurship: The Business of Biotech
This is part of the MaRS BioEntrepreneurship series.
Speaker: Lynne Zydowsky, Ph.D., Managing Principal Zydowsky Consultants
* Explore the development of regulated drugs and devices
* Understand where and how value is generated in the pharmaceuticals industry
* Appreciate the interplay between science and business in a biotech company
To download a copy of the audio for this presentation, please go to:
http://www.marsdd.com/bioent/oct16
For the event blog and Q+A, please see:
http://blog.marsdd.com/2006/10/17/bringing-together-art-and-science/
Day 2: Danielle Rollmann, MIT FoCUS (Nov 19) Access to Innovation Conference ...
Day 2: Danielle Rollmann, MIT FoCUS (Nov 19) Access to Innovation Conference ...Canadian Organization for Rare Disorders
This document summarizes work by the MIT Center for Biomedical Innovation on analyzing the cell and gene therapy pipeline. It estimates that there will be approximately 80-100 new gene and cell therapy product approvals in the United States by 2031, treating around 410,000-550,000 patients. The majority of these therapies will be for oncology (cancer) patients. It also provides estimates of total reimbursement for these new therapies in 2031 of $20-30 billion, with $15-21 billion for oncology treatments. Near term therapies discussed include already approved CAR-T cancer therapies and gene therapies for rare diseases like spinal muscular atrophy.Nw biotech fundamentals day 2 session 1 introduction
Welcome to Day 2 of the Biotech fundamentals course, recap of day 1 learnings and overview of the day’s Agenda, covering:
• Medical devices and diagnostics
• Industrial applications and CleanTech
• Aquaculture
• Agriculture
More Related Content
What's hot
HealthBIO 2020_Prateek Singh_Finnadvance
The document discusses the inefficiencies and high costs of current drug development processes, which rely on animal and 2D cell culture models that do not adequately represent human biology. As a result, 90% of drugs validated in these non-human models fail during human clinical trials. The CEO of Finnadvance, Prateek Singh, proposes that Organ-on-Chip models could help address these issues by providing more representative human models that could save hundreds of millions of dollars and years in the drug development timeline by identifying ineffective drugs earlier. Finnadvance is developing human disease-on-chip platforms using patient-derived cells to model conditions like rare vascular malformations.
Holobiome final presentation 7
Holobiome aims to provide personalized probiotics to help inflammatory bowel disease (IBD) patients remain in remission naturally without side effects. After testing various customer segments, they determined IBD patients were the best fit. Holobiome will partner with suppliers to grow specialized probiotics and conduct research to publish their findings. Their goals are to help patients through cost savings and reduced symptoms while generating revenue through probiotic sales to patients and prescriptions from gastroenterologists.
Hy genesis b - wecan - pitch 160303
This document summarizes a company called HyGenesis that has developed long-lasting antimicrobial technologies to reduce infections. It discusses the problems of hospital and healthcare-acquired infections (HAIs), including the human and financial toll of antibiotic-resistant strains like MRSA. HyGenesis has created Hand Armor and Surface Armor products that provide hours to months of antimicrobial protection through a mechanical killing mechanism. Studies at hospitals and universities have shown the technologies effectively kill pathogens. Management is seeking $350,000 in funding to continue product development and scaling operations to achieve $49 million in global sales by 2020 by targeting the ambulatory care market through multiple sales channels.
Molecular basis of response to (sub)lethal stresses in Tephritid fruit flies
Molecular basis of response to (sub)lethal stresses in Tephritid fruit fliesPlant Biosecurity Cooperative Research Centre
This document summarizes a research project studying the molecular response of tephritid fruit flies to sublethal stresses. The project aims to:
1) Identify the molecular pathways activated in fruit flies exposed to heat, cold, radiation, and parasitic infection stresses.
2) Construct a regulatory network of stress response genes in two key fruit fly pests.
3) Validate specific genes' roles in stress response through functional assays.
The goal is to develop more effective and environmentally friendly postharvest treatments for controlling fruit flies, providing benefits to the horticulture industry, government pest management strategies, and researchers.Nanotechnology in Medical Devices
Nanotechnology is the science of understanding, inventing, and controlling objects which are built in the scales of nanometers (one nanometer is one-billionth of a meter). Using Nanotechnology, manufacturers can compose components such as batteries, robots, or tools at a very small scale which may be later added to medical devices. With advanced scientific developments over a decade, Nanotechnology is proving itself to be useful in the healthcare domain including alternative drug production, cosmetic products, and medical devices. As, in such cases, human safety is the highest priority, these devices or applications which utilize Nanotechnology should be FDA compliant before they are marketed for use...
What to Expect after Getting a COVID-19 Vaccine
Getting a COVID-19 vaccine may cause side effects like pain, swelling, tiredness, or fever, which are signs that the body is building immunity. These side effects should go away within a few days. If side effects persist or worsen after 24 hours, contact a doctor. Taking over-the-counter medicines can help relieve discomfort. Getting the recommended second dose is important even if the first caused side effects, unless a provider advises otherwise.
Covid 19, vaccine and it's development process - Group 1
The document summarizes COVID-19, the development of vaccines for COVID-19, and compares the traditional vaccine development process to the COVID-19 vaccine development process. Specifically:
1) It provides background on COVID-19, describing the virus, symptoms, and transmission routes.
2) It discusses the global effort to develop COVID-19 vaccines, with over 157 candidates in development as of June 2020 and 16 in clinical trials.
3) It summarizes the AstraZeneca/Oxford AZD1222 vaccine, how it works, and results from Phase 1/2 clinical trials showing an immune response.
4) It compares the traditional long vaccine development process, taking 6-20 years, to the accelerated
Global vaccine market Keyword Market PPT 2021-26 | Enhancing Huge Growth and ...
According to the latest report by IMARC Group the global vaccine market size reached a strong growth in 2020.One of the leading trends witnessed in the global vaccines market is the surging cases of the coronavirus disease (COVID-19), which has, till date, resulted in the loss of around half a million lives around the world Looking forward, the market value is projected to reach a strong growth during the forecast period (2021-2026).
All about Covid-19 Vaccine Development
Disclaimer -
The Content belongs to WHO (World Health Organisation). Sharing here is just to spread awareness about Covid-19.
https://www.who.int/docs/default-source/coronaviruse/risk-comms-updates/update37-vaccine-development.pdf?sfvrsn=2581e994_6
Jessica Rockwood-Enfermedades transmitidas por vectores
El 12 de mayo de 2017 celebramos en la Fundación Ramó Areces una jornada con IS Global y Unitaid sobre enfermedades transmitidas por vectores, como la malaria, entre otras.
Julian Entwistle Ian-Enfermedades transmitidas por vectores
El 12 de mayo de 2017 celebramos en la Fundación Ramó Areces una jornada con IS Global y Unitaid sobre enfermedades transmitidas por vectores, como la malaria, entre otras.
Early and accurate detection of bacterial pathogens
This document summarizes a research project that aims to develop accurate and rapid diagnostic tools for detecting exotic bacterial plant pathogens through genome-informed design. The project is developing PCR and LAMP-based diagnostics for key pathogens like Erwinia amylovora and Xanthomonas citri. Field-deployable tools like LAMP and RPA are also being validated for "smart surveillance" directly in the field. The diagnostics and training provided by this research will benefit biosecurity agencies, diagnostic laboratories, and the horticultural industry by facilitating early detection and a rapid response to incursions.
Medical product development & victoria
Victoria, Australia provides eight compelling reasons for undertaking medical product development:
1. Unsurpassed research infrastructure with ongoing research in many medical fields creating new intellectual property daily.
2. Enviable research services infrastructure including three universities doing medical research, and facilities for synchrotron use, nanofabrication, imaging, cytometry, mass spectrometry, microscopy, and pathology.
3. A world class product design and development industry with five ISO13485 accredited consulting groups having deep experience designing products for global certification and markets across many medical product categories.
Biosimilar Development EPTM 2015
Sharing my learning in dealing with complexity and uncertainty and shed some light on:
(a) Understanding the ‘biosimilar paradox’
(b) Accelerating our “QbD” Journey – focusing on ‘from Generics to Biosimilars’
(c) In preparing this talk, collect my thoughts to help NIPTE consider ways for developing its program on Biosimilars to help the Nation improve assurance of quality with confidence and lower costs
(D) Invite the audience to get to know NIPTE and provide us ways to collaborate with industry
Medical Device Biocompatibility
If your medical device has contact with human tissue, it is a safe bet that you will be required to conduct biocompatibility testing. Biocompatibility testing is used to determine the “potential for an unacceptable adverse biological response resulting from contact of the component materials of the device with the body”. The FDA relies heavily on ISO 10993 as the guiding force for biocompatibility testing in medical devices. This ISO standard is rooted in a risk-based approach to testing that the FDA views as the gold standard to ensure that medical devices do not cause adverse local or systemic effects due to contact with human tissue...
Verica mktg 06092010summary
The document summarizes a marketing plan for the Verica Sightline 3D Guided Needle Biopsy System. It describes the unmet need in the field of needle biopsies, specifically the emotional and physical costs to patients from inaccurate or multiple needle insertions. The Verica Sightline aims to improve reliability, safety, and efficiency of biopsies through 3D ultrasound guidance. Key points covered include the target clinical problem, value proposition, market size analysis, and competitive landscape for this medical device product.
BatchMaster ERP for Vaccines
Vaccine development is just the first step in eradicating the pandemic, the real challenge lies in managing and handling its supply chain. An ERP built specifically for Vaccines can be the way out in efficiently fighting these challenges. Go through the presentation to know how exactly an ERP for vaccines helps.
Therapeutic Targeting of Alzheimer's Disease with a Selective Antibody
Whiteboard2Boardroom presents innovations from regional universities, hospitals, research organizations to encourage commercialization.
Urology billing-surgical-supply-growth-and-market-share
According to the new released data companies supplying surgical products for urology have stated that the demand is expected to grow by 10 percent CAGR.
What's hot (19)
Molecular basis of response to (sub)lethal stresses in Tephritid fruit flies
Molecular basis of response to (sub)lethal stresses in Tephritid fruit flies
Covid 19, vaccine and it's development process - Group 1
Covid 19, vaccine and it's development process - Group 1
Global vaccine market Keyword Market PPT 2021-26 | Enhancing Huge Growth and ...
Global vaccine market Keyword Market PPT 2021-26 | Enhancing Huge Growth and ...
Jessica Rockwood-Enfermedades transmitidas por vectores
Jessica Rockwood-Enfermedades transmitidas por vectores
Julian Entwistle Ian-Enfermedades transmitidas por vectores
Julian Entwistle Ian-Enfermedades transmitidas por vectores
Early and accurate detection of bacterial pathogens
Early and accurate detection of bacterial pathogens
Therapeutic Targeting of Alzheimer's Disease with a Selective Antibody
Therapeutic Targeting of Alzheimer's Disease with a Selective Antibody
Urology billing-surgical-supply-growth-and-market-share
Urology billing-surgical-supply-growth-and-market-share
Similar to Wichita State University (WSU), Antibiotics for Drug-Resistant Bacteria
BioEntrepreneurship: The Business of Biotech
This is part of the MaRS BioEntrepreneurship series.
Speaker: Lynne Zydowsky, Ph.D., Managing Principal Zydowsky Consultants
* Explore the development of regulated drugs and devices
* Understand where and how value is generated in the pharmaceuticals industry
* Appreciate the interplay between science and business in a biotech company
To download a copy of the audio for this presentation, please go to:
http://www.marsdd.com/bioent/oct16
For the event blog and Q+A, please see:
http://blog.marsdd.com/2006/10/17/bringing-together-art-and-science/
Day 2: Danielle Rollmann, MIT FoCUS (Nov 19) Access to Innovation Conference ...
Day 2: Danielle Rollmann, MIT FoCUS (Nov 19) Access to Innovation Conference ...Canadian Organization for Rare Disorders
This document summarizes work by the MIT Center for Biomedical Innovation on analyzing the cell and gene therapy pipeline. It estimates that there will be approximately 80-100 new gene and cell therapy product approvals in the United States by 2031, treating around 410,000-550,000 patients. The majority of these therapies will be for oncology (cancer) patients. It also provides estimates of total reimbursement for these new therapies in 2031 of $20-30 billion, with $15-21 billion for oncology treatments. Near term therapies discussed include already approved CAR-T cancer therapies and gene therapies for rare diseases like spinal muscular atrophy.Nw biotech fundamentals day 2 session 1 introduction
Welcome to Day 2 of the Biotech fundamentals course, recap of day 1 learnings and overview of the day’s Agenda, covering:
• Medical devices and diagnostics
• Industrial applications and CleanTech
• Aquaculture
• Agriculture
Global bispecific antibody market & clinical pipeline insight 2020
“Global Bispecific Antibody Market & Clinical Pipeline Insight 2020” Report Highlights:
Overview of Bispecific Antibody
Mechanism of Action of Bispecific Antibody
Design & Engineering of Bispecific Antibodies
Applications of Bispecific Antibodies
Global Bispecific Antibodies Clinical Pipeline by Company, Indication & Phase
Global Bispecific Antibodies Clinical Pipeline: 123 Bispecific Antibodies
Marketed Bispecific Antibodies: Blinatumomab (Blincyto) & Catumaxomab (Removab)
Innovative Medical Devices: Developing Multidisciplinary Safety & Efficacy Te...
The document discusses strategies for developing multidisciplinary safety and efficacy testing for medical devices and combination products to combat healthcare-associated infections. It highlights the issues of antibiotic resistance and emerging pathogens. Various new product designs and engineering solutions are presented as case studies, along with the need for safety testing that includes biocompatibility, microbiology, chemical characterization, and toxicology. Regulatory requirements and guidelines for combination products involving drugs or biologics are also reviewed.
Nw biotech fundamentals day 1 session 5 life sciences
This presentation covers:
• Definition of life sciences
• The stages of a therapeutic drugs or vaccines R&D project
• The state of the art
• Regulatory nuances
• Pre-clinical and in the clinic issues
• Future trends
• Challenges and opportunities
• Case studies and examples
Organs-On-Chips - 2017 Report by Yole Developpement
Currently worth a few million dollars, the emerging organs-on-chips market has the potential to become a multi-billion dollar market.
Organs-on-chips: the promise of solving one of the pharmaceutical industry’s major hurdles
Bringing a new drug to market is one of the longest and most costly paths any industry has to walk. Companies start with several thousands of compounds that may have positive effects against a disease or a human condition. More than twelve years and several billion dollars later, if they’re lucky they managed to get one of these compounds onto the market. All the others failed at one stage or another during the drug development process – and the later the failure, the more expensive it is. Current methods – cell culture in petri dishes and animal testing among others – are not predictive enough. Around 90% of drugs that have been validated on these models then fail during clinical trials because of toxicity or lack of efficacy. The pharmaceutical industry therefore needs more predictive tools to make drug candidates fail earlier and cheaper. Other industries where toxicity testing is a major concern, such as cosmetics, agro-food and consumer goods, also need such solutions, in particular because animal testing is now banned for these industries in certain geographical areas. Several options have been envisioned, the most promising of which is certainly organs-on-chips. These combinations of micro-technology and biology reconstitute the physiological and mechanical functions of human organs under the form of micro-engineered devices lined with living cells. Precisely controlled fluid flows combined with mechanical cues and tissue-tissue interfaces enable dynamic models, much more relevant than conventional static cell cultures. As a sign of confidence in this technology, significant funding has been allocated to organs-on-chips developers: DARPA and the NIH respectively awarded $140M and $76M over 5-year periods to support developments. In parallel, technology developers have raised more than $80M since 2012 with investors. In Yole Développement’s report, all the key elements to understand the organs-on-chips landscape are detailed.
For more information, please visit our website: https://www.i-micronews.com/reports.html
Nw biotech fundamentals day 2 session 5 summary and wrap up
A recap and summary of the two day course, covering:
• Medical devices and diagnostics
• Industrial applications and CleanTech
• Aquaculture
• Agriculture
• Further reading and resources
Download Global cancer immunotherapy market outlook 2020
\"Global Cancer Immunotherapy Market Outlook 2020\" Report Highlight:
Introduction & Classification of Cancer Immunotherapy
Global Cancer Immunotherapy Pipeline by Company, Indication & Phase
Marketed Cancer Immunotherapies Clinical Insight & Patent Analysis by Company & Indication
Global Cancer Immunotherapy Pipeline: 1834 Drugs
Marketed Cancer Immunotherapies: 113 Drugs
Cancer Monoclonal Antibodies Pipeline: 622 Cancer mAb
Cancer Vaccines Pipeline: 312 Vaccines
Marketed Cancer mAb: 36 mAb
Marketed Cancer Vaccines: 12 Vaccines
Global cancer immunotherapy market outlook 2020
The document provides an overview of the global cancer immunotherapy market outlook for 2020. It discusses how cancer immunotherapies work by modulating the immune system to treat cancer. The market has seen significant growth with many approved and pipeline immunotherapies across classes like monoclonal antibodies, cytokines, vaccines, and immune checkpoint inhibitors. The market is expected to continue growing in coming years due to increased research and funding leading to new treatment modalities and biomarkers to expand the use of immunotherapies for additional cancer types.
Biosimilars global congress 2014 europe copy 3 (6)
Biosimilars Global Congress 17-19 September 2014 Hilton Kensington London. email chetan.patel@paradigmglobalevents.com for early bird prices.
Biosimilars
This document discusses biosimilars and their regulation. It begins with a brief history of biotechnology and biopharmaceuticals. It then defines biosimilars as similar but not generic versions of biologic drugs whose patents have expired. The document outlines key differences between biosimilars and generic drugs, including their larger and more complex molecular structures. It also discusses concerns regarding biosimilar efficacy, safety, interchangeability, and pharmacovigilance. Finally, it provides an overview of regulatory frameworks for biosimilars in various regions like the EU, US, India, and WHO guidelines.
6th biosimilars congregation 2015
Dear Ladies & Gentlemen,
Hope all is well, Glad to share details with you of our upcoming conference “6th Biosimilars 2015” taking place on 10th & 11th March 2015, The Kensington Close Hotel, Wrights Lane, London, UK. Please find attached the updated agenda for the same with this email.
In case you and your colleagues would like to book as delegate there is a discounted price now :-
Introductory Offer (3 delegate places for the price of 2):- A huge saving of £ 600
Super Early Discount (Till 26th December 2014):- Conference Delegate Pass (£ 600 + VAT per delegate)
We can also offer some other sponsorship packages which include speaking opportunities/ branding etc. For some sample packages on the same please email me and I can call you to discuss the options further.
For any further assistance please feel free to contact me anytime. I look forward to a positive response from your end.
Best Regards,
Deepak Raj
Delegate and Sponsorship Sales
Virtue Insight
Gsm - + 91 9171350244;
UK Diagnostics Summit Presentations
The document discusses the key role of diagnostics in addressing the challenge of antimicrobial resistance (AMR). It makes three key points:
1) AMR is a major threat as many infections are becoming increasingly difficult to treat due to drug-resistant bacteria. Without effective antibiotics, common infections and surgeries could become life-threatening.
2) Diagnostics are critical to appropriate antibiotic use by enabling rapid and precise diagnosis of whether a bacterial or viral infection is present and, if bacterial, determining the best antibiotic to use or avoid. This can help reduce unnecessary antibiotic prescribing.
3) The document outlines a vision for AMR diagnostics in the UK to ensure rapid diagnostic technologies are universally available to guide antibiotic
Genentech
Genentech was the first biotech company founded in 1976 with the goal of using recombinant DNA technology to develop new drugs. It successfully transferred genes between species and established a new business model in the pharmaceutical industry. While Genentech initially struggled to profit from its technology, by the late 1980s it began showing promising results by altering its business model to focus on areas like oncology, immunology, and neuroscience. It became the first biotech company to go public and bring a genetically engineered drug to market.
Lustrumlezing paul stoffels de rol van innovatie voor de gezondheidszorg van ...
Ter gelegenheid van het 40 jarig bestaan van de Universiteit werd een reeks lustrumlezingen georganiseerd. Voor de faculteit Gezondheid en Levenswetenschappen hadden we de eer Dr. Paul Stoffels - Worldwide Chairman , Janssen Pharmaceutical Chief Scientific Officer, Johnson & Johnson - te mogen ontvangen.
Presentation - New Business Models for Antibiotics: Where Are We Now? 16 Marc...
Presentation - New Business Models for Antibiotics: Where Are We Now? 16 Marc...Office of Health Economics
Speaking at the Superbugs & Superdrugs conference in London on 16 March 2016, OHE’s Jorge Mestre-Ferrandiz delivered a presentation on financial and collaborative incentives to accelerate clinical success for antibiotics.
Jorge discussed the economic challenges around antibiotics, and whether there is a need for a new business model. He reviewed of the impact of previous incentives, explaining what has worked in the past, and discussed possible new business models.
P 151 biosimilars & biobetters
This document provides information about a conference on biosimilars taking place from September 30th to October 1st, 2015 in London. The conference will discuss the evolving regulatory landscape for biosimilar approval in the US and Europe, market access challenges, protein characterization, and analytical comparability. It includes an agenda with sessions on the regulatory processes, patent litigation, pharmacovigilance, clinical development strategies, and analytical techniques for assessing biosimilarity. Pre-conference and post-conference workshops will provide more in-depth discussions of these topics.
2-McGroarty_SEMIC Rome 2016 FMG(1).pptx
This document provides a case study on how adopting global standards enabled interoperability and improved patient safety and supply chain efficiency for medication management of hemophilia patients in Ireland. It discusses how GS1 standards were implemented, including barcoding of medications, patients, and locations. This allowed medications to be tracked from manufacturer to patients' homes and improved recall capabilities. Outcomes included validated cold chain delivery, reduced documentation errors, improved stock rotation savings, and the ability to locate all medication during a mock recall. The smartphone app further enabled real-time medication recalls, improved compliance monitoring, and significant early cost savings. The document concludes that standards like those from GS1 are key to improving patient safety and reducing healthcare costs through more efficient supply chain
Biosimilars
The document discusses biosimilars and the regulatory pathway for biosimilar approval in India. It provides background on biosimilars and how they differ from generics in terms of manufacturing complexity and clinical development requirements. It summarizes India's draft biosimilar guidelines, including that phase III trials with 100+ patients are required for approval but phase I-II may be waived. The guidelines aim to streamline the process while aligning with global standards from the EMA and WHO. Over 20 biosimilars have been approved in India across several therapeutic classes.
Similar to Wichita State University (WSU), Antibiotics for Drug-Resistant Bacteria (20)
Day 2: Danielle Rollmann, MIT FoCUS (Nov 19) Access to Innovation Conference ...
Day 2: Danielle Rollmann, MIT FoCUS (Nov 19) Access to Innovation Conference ...
Nw biotech fundamentals day 2 session 1 introduction
Nw biotech fundamentals day 2 session 1 introduction
Global bispecific antibody market & clinical pipeline insight 2020
Global bispecific antibody market & clinical pipeline insight 2020
Innovative Medical Devices: Developing Multidisciplinary Safety & Efficacy Te...
Innovative Medical Devices: Developing Multidisciplinary Safety & Efficacy Te...
Nw biotech fundamentals day 1 session 5 life sciences
Nw biotech fundamentals day 1 session 5 life sciences
Organs-On-Chips - 2017 Report by Yole Developpement
Organs-On-Chips - 2017 Report by Yole Developpement
Nw biotech fundamentals day 2 session 5 summary and wrap up
Nw biotech fundamentals day 2 session 5 summary and wrap up
Download Global cancer immunotherapy market outlook 2020
Download Global cancer immunotherapy market outlook 2020
Biosimilars global congress 2014 europe copy 3 (6)
Biosimilars global congress 2014 europe copy 3 (6)
Lustrumlezing paul stoffels de rol van innovatie voor de gezondheidszorg van ...
Lustrumlezing paul stoffels de rol van innovatie voor de gezondheidszorg van ...
Presentation - New Business Models for Antibiotics: Where Are We Now? 16 Marc...
Presentation - New Business Models for Antibiotics: Where Are We Now? 16 Marc...
More from kphodel
Antiviral Compounds Against SARS-COV-2
Whiteboard2Boardroom collaborates with more than 21 research institutions, hospitals and corporation to move technologies out of research labs into the marketplace.
Co-Immunity Presentation
Whiteboard2Boardroom collaborates with more than 21 research institutions, hospitals and corporation to move technologies out of research labs into the marketplace.
Co-Immunity Presentation
Whiteboard2Boardroom collaborates with more than 21 research institutions, hospitals and corporation to move technologies out of research labs into the marketplace.
Improved Jacketing Repair System For Steel H Beams
Whiteboard2Boardroom presents innovations from regional universities, hospitals, research organizations to encourage commercialization.
Nucleotide-Based Diagnostic for Infectious Diseases
Whiteboard2Boardroom presents innovations from regional universities, hospitals, and research organizations to encourage commercialization.
Non-Invasive Bowel monitoring system
Whiteboard2Boardroom presents innovations from regional universities, hospitals, and research organizations to encourage commercialization.
Securing edge lot systems
Whiteboard2Boardroom presents innovations from regional universities, hospitals, and research organizations to encourage commercialization.
Pandemic tent
Whiteboard2Boardroom presents innovations from regional universities, hospitals, research organizations to courage commericalization.
Dual function camera webinar presentation
"Whiteboard2Boardroom presents innovations from regional universities, hospitals, research organizations to encourage commericalization.
4.23.2020 webinar presentation for website
Whiteboard2Boardroom presents innovations from regional universities, hospitals, research organizations to encourage commercialization.
4.23.2020 W2B Webinar Presentation
Whiteboard2Boardroom presents innovations from regional universities, hospitals, research organizations to encourage commercialization
Mizzou bio joint flex snapshot
This webinar aims to attract entrepreneurs and corporations to license two technologies presented: the Mizzou BioJoint Flex knee range of motion device. The webinar will include 10-minute presentations on each technology and a question period. The BioJoint Flex addresses knee arthrofibrosis by providing a gentle, prolonged stretch at home or in a clinic. It has undergone initial clinical trials demonstrating benefits in flexion, function, pain and satisfaction over physical therapy. Further development needs include finding a licensing partner for manufacturing and marketing, finalizing the patient and pro versions, pursuing 510k clearance, and commercialization. The presentation provides details on intellectual property, development stage, clinical results, market opportunity, competition, and the development team.
W2B High Scurity Circuit Boards
Whiteboard2Boardroom presents innovations from regional universities, hospitals, research organizations to encourage commercialization.
W2B Electromagnetic Launchers
Whiteboard2Boardroom presents innovations from regional universities, hospitals, research organizations to encourage commercialization.
Ergo stm snapshot 3.26
Whiteboard2Boardroom presents innovations from regional universities, hospitals, research organizations to encourage commercialization.
Snap shot lever 2019 website version
Whiteboard2Boardroom presents innovations from regional universities, hospitals, research organizations to encourage commercialization.
Snap shot lever 2019
The webinar aims to (1) attract entrepreneurs to license technologies to start companies, (2) attract corporations to license technologies for new products, and (3) solicit input on commercial viability. The agenda includes a schedule, two 10-minute technology presentations on medical devices to diagnose swallowing disorders, and a question period. The first device, Down the Hatch, provides objective data from endoscopy videos to diagnose and prevent aspiration pneumonia. The second, Tongue Twister, is a mobile app that provides objective data on speech and swallowing tasks to assess patients. Both technologies are patent-pending and seeking start-up partners for further development and commercialization.
Trait for flood & drought resistance in plants
Whiteboard2Boardroom presents innovations from regional universities, hospitals, research organizations to encourage commercialization.
Novel Tool to Optimize Complex Industrial Projects
Whiteboard2Boardroom presents innovations from regional universities, hospitals, research organizations to encourage commercialization.
Novel tool to optimize complext industrial projects
Whiteboard2Boardroom presents innovations from regional universities, hospitals, research organizations to encourage commercialization.
More from kphodel (20)
Improved Jacketing Repair System For Steel H Beams
Improved Jacketing Repair System For Steel H Beams
Nucleotide-Based Diagnostic for Infectious Diseases
Nucleotide-Based Diagnostic for Infectious Diseases
Trait for flood & drought resistance in plants
Trait for flood & drought resistance in plants
Novel Tool to Optimize Complex Industrial Projects
Novel Tool to Optimize Complex Industrial Projects
Novel tool to optimize complext industrial projects
Novel tool to optimize complext industrial projects
Recently uploaded
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.share - Lions, tigers, AI and health misinformation, oh my!.pptx
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
STIs may cause PID. For the both disease, herbal medicine Fuyan Pill can be a solution.
Top 10 Best Ayurvedic Kidney Stone Syrups in India
we have mentioned the best 10 ayurvedic Kidney Stone Syrups. You can check all these products and choose the best one for yourself.
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...chandankumarsmartiso
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun Women Seeking Service
Cell Therapy Expansion and Challenges in Autoimmune Disease
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Role of Mukta Pishti in the Management of Hyperthyroidism
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Efficacy of Avartana Sneha in Ayurveda
Avartana Sneha is a unique method of Preparation of Sneha Kalpana in Ayurveda, mainly it is indicated for the Vataja rogas.
The Best Ayurvedic Antacid Tablets in India
Treat the symptoms of indigestion, heartburn and stomach reflux with the 10 Best Ayurvedic Antacid Tablets in India.
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler Community Health Nursing A Canadian Perspective, 5th Edition TEST BANK by Stamler Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Study Guide Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Studocu Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Course Hero Community Health Nursing A Canadian Perspective, 5th Edition Answers Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Course hero Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Studocu Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Study Guide Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Ebook Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Questions Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Studocu Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Stuvia
Adhd Medication Shortage Uk - trinexpharmacy.com
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
The Electrocardiogram - Physiologic Principles
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Histololgy of Female Reproductive System.pptx
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
Recently uploaded (20)
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
Role of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of Hyperthyroidism
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
Wichita State University (WSU), Antibiotics for Drug-Resistant Bacteria
- 1. Antibiotics for Drug-Resistant Bacteria April 24, 2018 Jason DeGarmo – WSU Ventures Wichita State University
- 2. What is the problem? • The rise of antibiotic-resistant ‘superbugs’ • Problematic issues – Conventional antibiotics are making the problem worse – High exposure environments • Current and future impacts – More than 23,000 U.S. deaths occur each year (CDC) – WHO predicts 10 million deaths worldwide by 2050 – Mortality rate for septic wounds is high (20%)
- 3. How does product/service solve problem? • Wichita State developed new class of antibiotics – Termed “Liptin” • New mechanism of action • Shown effective against: – Gram-positive bacteria species – Gram-negative bacteria species – Mycobacterium species Liptin compound binding to top of the PG head group
- 4. What is the market use? • Pharmaceutical industry needs new classes of antibiotics • Pharmaceutical Industry – World market value: $1.4 trillion • Antibiotics: $42 billion – Impacts other medical industries dependent on immunosuppressant’s • Surgery/Transplants (ex. organ, bone marrow) • Medical device implantation • Chemotherapy
- 5. What competition exists? • "Big Pharma" companies – Gateway controllers – Competitors Licensee • Chronic vs. Acute diseases
- 6. What is the status of the intellectual property? • Patent Pending – Application published in July 2017 – WO/2017/132561 A1
- 7. What is the stage of development? • Positive initial in-vitro results – Bactericidal effects observed • Min. Inhibitory Concentration - ~5 micromolar – Depolarization studies support Liptin mechanism • Tested bacterial cell lines include: – Escherichia coli – Staphylococcus aureus – MRSA – Mycobacterium smegmatis – Enterococcus faecium – Klebsiella pneumoniae – Acinetobacter baumannii – Pseudomonas aerjinosa
- 8. • Depolarization study • Live/Dead assay (90 minutes after 5 micromolar inoculation) Test Results
- 9. What is needed for further development? • Gap-funding to move past the "valley of death" – To perform initial bioavailability ($20k) before conducting extensive in-vivo testing ($150k-$200k) • Potential connections for industry collaboration • Bottom Line: • Favorable bioavailability results will place this technology in a position where more investment can be sought out and secured
Editor's Notes
- Common targets for conventional antibiotics: Cell wall, DNA, Ribosomes High exposure environments – Hospitals Armed Forces deployment areas
- Why are these compounds effective? GENERAL TARGET – PG head group. PG location is unique and present (varying %) in all bacteria plasma membranes One target – shockwave sent across the plasma membrane and numerous effects observed Both bacterial -static and -cidal
- What we've learned from nature: Bacterial resistance is always going to win Essentially, the market (humanity/big pharma) are never going to win in the long run against bacteria. All we can do is provide enough tools to fight. Bacteria have never seen this (liptin) mechanism of action before
- Leaders include: Debiopharm SA (affinium) Theravance Biopharma GlaxoSmithKline (Novartis) Merck & Co Melinta Therapeutics